SG10201510249PA - Insulinotropic peptide derivative wherein its n-terminal amino acid is modified - Google Patents

Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Info

Publication number
SG10201510249PA
SG10201510249PA SG10201510249PA SG10201510249PA SG10201510249PA SG 10201510249P A SG10201510249P A SG 10201510249PA SG 10201510249P A SG10201510249P A SG 10201510249PA SG 10201510249P A SG10201510249P A SG 10201510249PA SG 10201510249P A SG10201510249P A SG 10201510249PA
Authority
SG
Singapore
Prior art keywords
modified
amino acid
terminal amino
peptide derivative
insulinotropic peptide
Prior art date
Application number
SG10201510249PA
Inventor
Dae Hae Song
Chang Ki Lim
Young Hoon Kim
Se Chang Kwon
Gwan Sun Lee
Sung Min Bae
Sung Youb Jung
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of SG10201510249PA publication Critical patent/SG10201510249PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG10201510249PA 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified SG10201510249PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070071071 2007-07-16
US99115507P 2007-11-29 2007-11-29

Publications (1)

Publication Number Publication Date
SG10201510249PA true SG10201510249PA (en) 2016-01-28

Family

ID=40260219

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201510249PA SG10201510249PA (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
SG10201510245SA SG10201510245SA (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
SG2012052114A SG183033A1 (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201510245SA SG10201510245SA (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
SG2012052114A SG183033A1 (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Country Status (22)

Country Link
US (1) US9422349B2 (en)
EP (4) EP2537861B1 (en)
JP (7) JP2009019027A (en)
KR (1) KR101231431B1 (en)
CN (2) CN101778863A (en)
AR (1) AR067555A1 (en)
AU (1) AU2008276762A1 (en)
BR (1) BRPI0814097A8 (en)
CA (3) CA2693154C (en)
DK (1) DK2390265T3 (en)
ES (3) ES2528347T3 (en)
HK (1) HK1207088A1 (en)
IL (1) IL203288A (en)
MY (1) MY167486A (en)
NZ (3) NZ594853A (en)
PH (2) PH12014500922A1 (en)
PT (1) PT2390265E (en)
RU (1) RU2442792C2 (en)
SG (3) SG10201510249PA (en)
TW (3) TWI454276B (en)
WO (1) WO2009011544A2 (en)
ZA (1) ZA201000125B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009019027A (en) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
MY150536A (en) 2009-03-20 2014-01-30 Hanmi Science Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
MX2012005912A (en) 2009-11-23 2012-10-05 Amylin Pharmaceuticals Inc Polypeptide conjugate.
KR101382593B1 (en) * 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
PL3241558T3 (en) 2010-09-28 2021-08-30 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
EA201390450A1 (en) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. POLYPEPTIDES WITH INCREASED DURATION OF ACTION
JP2014521594A (en) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Long duration dual hormone conjugate
UA113626C2 (en) 2011-06-02 2017-02-27 A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
CN104271588B (en) 2011-07-08 2017-10-10 安米林药品有限责任公司 The engineered polypeptide of immunogenicity with enhanced acting duration and reduction
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
CN103130889A (en) * 2012-06-15 2013-06-05 中国药科大学 Exendin-4 analogue, preparation method thereof and application Exendin-4 analogue
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
AR092862A1 (en) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
KR20140088837A (en) * 2013-01-03 2014-07-11 한미약품 주식회사 Insulinotropic peptide derivative wherein its N-terminal charge is modified
AR096891A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
AR096890A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATING FC OF IMMUNOGLOBULINA, THAT MAINTAINS THE UNION AFFINITY OF THE FC FRAGMENT OF THE IMMUNOGLOBULIN TO FCRN
CA2937168A1 (en) 2014-01-20 2015-07-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
HU231358B1 (en) 2014-03-31 2023-03-28 Hanmi Pharm. Co., Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AR100639A1 (en) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
AR100695A1 (en) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES THAT INCLUDES INSULIN AND A DUAL AGONIST GLP-1 / GLUCAGÓN
US11123436B2 (en) 2015-07-24 2021-09-21 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
UY36870A (en) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd NEW INSULIN ANALOGS
US20190055279A1 (en) * 2015-10-28 2019-02-21 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
CA3037844A1 (en) 2016-09-23 2018-03-29 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
CN110291103A (en) 2016-12-05 2019-09-27 韩美药品株式会社 The conjugate of immune response with reduction
JP2020506932A (en) 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド Conjugates of bioactive substances with increased persistence and uses thereof
WO2018174668A2 (en) 2017-03-23 2018-09-27 한미약품 주식회사 Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (en) 2021-06-25 2023-01-03 한미약품 주식회사 Efpeglenatide for reducing the risk of developing cardiovascular diseases or renal dysfunction
KR20230010571A (en) 2021-07-12 2023-01-19 한미약품 주식회사 A composition for oral administration comprising GLP-1 analog
WO2023194390A1 (en) * 2022-04-08 2023-10-12 Danmarks Tekniske Universitet Histidine methyltransferase for increased peptide and protein stability

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7A (en) * 1836-08-10 Thomas blanchard
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
KR100600457B1 (en) 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 Exendin analogues, processes for their preparation and medicaments containing them
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
DK0944648T3 (en) * 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivatives
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002507188A (en) 1996-08-30 2002-03-05 イーライ・リリー・アンド・カンパニー Use of glucagon-like peptide-1 (GLP-1) or a homolog thereof to prevent catabolic modulation after surgery
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
EP1938831A1 (en) 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056775B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
PL346317A1 (en) 1998-08-28 2002-01-28 Lilly Co Eli Method for administering insulinotropic peptides
PL393178A1 (en) 2000-12-07 2011-02-14 Eli Lilly And Company Heterogeneous fusion protein, pharmaceutical composition for the treatment of diabetic patients with insulin-independent diabetes and pharmaceutical composition for the treatment of obese patients
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
MXPA05003335A (en) * 2002-10-02 2005-07-05 Zealand Pharma As Stabilized exendin-4 compounds.
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
WO2004056313A2 (en) * 2002-12-17 2004-07-08 Amylin Pharmaceuticals, Inc. Prevention and treatment of cardiac arrhythmias
JP2006514649A (en) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド Composition for the treatment and prevention of nephropathy
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
BRPI0608516A2 (en) * 2005-03-18 2010-11-16 Novo Nordisk As glp-1 analog, method for increasing the time of action in a patient of a glp-1 analog, pharmaceutical composition, and use of a compound
DK2347762T3 (en) * 2005-08-19 2019-06-11 Amylin Pharmaceuticals Llc EXENDIN FOR TREATMENT OF DIABETES AND REDUCTION OF BODY WEIGHT
WO2007063907A1 (en) 2005-11-30 2007-06-07 Shionogi & Co., Ltd. Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient
WO2008019147A2 (en) * 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
JP2008169195A (en) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2009019027A (en) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine

Also Published As

Publication number Publication date
JP6023516B2 (en) 2016-11-09
AR067555A1 (en) 2009-10-14
JP2014094948A (en) 2014-05-22
WO2009011544A2 (en) 2009-01-22
CA2789112A1 (en) 2009-01-22
RU2442792C2 (en) 2012-02-20
RU2010101232A (en) 2011-07-27
JP5481377B2 (en) 2014-04-23
CA2789112C (en) 2015-01-20
ES2528346T3 (en) 2015-02-09
PT2390265E (en) 2014-02-12
CN101778863A (en) 2010-07-14
PH12014500923A1 (en) 2016-03-07
EP2176289A4 (en) 2010-10-27
TWI524896B (en) 2016-03-11
HK1207088A1 (en) 2016-01-22
EP2537860B1 (en) 2014-11-26
CA2693154C (en) 2014-09-09
JP2010533709A (en) 2010-10-28
CA2693154A1 (en) 2009-01-22
KR101231431B1 (en) 2013-02-07
ES2528347T3 (en) 2015-02-09
NZ596828A (en) 2012-03-30
EP2390265A2 (en) 2011-11-30
TW200922615A (en) 2009-06-01
SG183033A1 (en) 2012-08-30
DK2390265T3 (en) 2014-02-10
BRPI0814097A8 (en) 2016-01-12
IL203288A (en) 2016-02-29
TWI454276B (en) 2014-10-01
JP2009019027A (en) 2009-01-29
CN104672319B (en) 2020-03-10
MY167486A (en) 2018-08-30
EP2537861B1 (en) 2014-11-26
US20100204451A1 (en) 2010-08-12
JP2013010779A (en) 2013-01-17
NZ582471A (en) 2012-01-12
TW201311272A (en) 2013-03-16
TW201311273A (en) 2013-03-16
WO2009011544A3 (en) 2009-03-19
EP2390265B1 (en) 2013-11-06
TWI532496B (en) 2016-05-11
EP2176289A2 (en) 2010-04-21
PH12014500922A1 (en) 2016-03-07
CA2789123A1 (en) 2009-01-22
JP2013014598A (en) 2013-01-24
EP2390265A3 (en) 2012-03-21
SG10201510245SA (en) 2016-01-28
BRPI0814097A2 (en) 2015-02-03
ES2444622T3 (en) 2014-02-26
AU2008276762A1 (en) 2009-01-22
CN104672319A (en) 2015-06-03
EP2537860A1 (en) 2012-12-26
ZA201000125B (en) 2011-04-28
JP6023515B2 (en) 2016-11-09
KR20090008151A (en) 2009-01-21
JP2015172058A (en) 2015-10-01
CA2789123C (en) 2015-01-06
US9422349B2 (en) 2016-08-23
EP2537861A1 (en) 2012-12-26
NZ594853A (en) 2012-03-30
JP2015166368A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
HK1207088A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified n-
HK1170941A1 (en) Oxyntomodulin peptide analogue
HK1170943A1 (en) Oxyntomodulin peptide analogue
EP2250278A4 (en) Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications
ZA201003681B (en) Compositions and methods comprising basic amino acid peptides and proteases
IL215348A0 (en) Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
HK1134029A1 (en) Amino acid composition
IL198186A (en) Mphosph1 derived peptide vaccines
IL195421A0 (en) Insulinotropic peptide synthesis
HK1210594A1 (en) Anti-fatigue agent comprising amino acid composition
HK1213916A1 (en) Biologically active c-terminal arginine-containing peptides c-
EP2270141A4 (en) Partial peptide of lacritin
HK1159074A1 (en) Amino acid derivative
EP2435468A4 (en) Fibromodulin peptide
EP2280024A4 (en) Polypeptide specifically coupled to phosphatidylserine and use thereof
GB0713189D0 (en) Amino acid derivatives
ZA200809190B (en) Amino acid surrogates for peptide constructs
EP2252310A4 (en) Heterocyclic peptide ketoamides
GB0715712D0 (en) Amino acid derivatives
PT2240200T (en) Therapeutic mannan linked mylein basic protein peptide mbp83-99
EP2244725A4 (en) Novel peptides and protein and uses thereof
GB0812586D0 (en) Chimaeric peptide
EP2123751A4 (en) Novel peptide